CoChat
Sign Up
Cited by 18Metabolism, Diabetes, and CancerCancer Risks and FactorsCancer, Hypoxia, and Metabolism

Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer

Open access
Yao, Kui, Zheng, Heng, Li, Tao·2022·Frontiers in Oncology
DOI 10.3389/fonc.2022.942380PMC PMC9309370
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: For gynecological cancer patients, the beneficial effect of metformin use remains controversial due to inconsistent results of published articles. By conducting a meta-analysis, we aimed to evaluate the effect of metformin in reducing the risk and improving the survival of gynecological cancer among women with diabetes mellitus (DM). Methods: Articles exploring association between metformin use and the risk, as well as prognosis of gynecologic cancer in DM, were searched in the databases: PubMed, Web of Science, SCOPUS, EMBASE, EBSCO, and PROQUEST. Articles were published before May 2022. All the studies were conducted using STATA 12.0 software. Results: The meta-analysis showed no significant association between metformin use and risk of gynecologic cancer in DM with a random effects model [odds ratio (ORs)/relative risk (RR) = 0.91, 95% confidence intervals (CI) 0.77 to 1.08, I 2 = 84.2%, p < 0.001]. Metformin use was associated with reduced overall survival (OS) and progression-free survival (PFS) of gynecologic cancer in DM with random effects models [OS: hazard ratio (HR) = 0.60, 95% CI 0.49–0.74, I 2 = 55.2%, p = 0.002; PFS: HR = 0.55, 95% CI 0.33–0.91, I 2 = 69.1%, p = 0.006], whereas no significant association was showed between metformin use and recurrence-free survival (RFS), as well as cancer-specific survival (CSS) of gynecologic cancer in DM with random effects models (RFS: HR = 0.60, 95% CI 0.30–1.18, I 2 = 73.7%, p = 0.010; CSS: HR = 0.78, 95% CI 0.43–1.41, I 2 = 72.4%, p = 0.013). Conclusions: In conclusion, this meta-analysis indicated that metformin may be a useful adjuvant agent for gynecological cancer with DM, especially for patients with ovarian cancer and endometrial cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2022.942380

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A meta-analysis found a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies, with hazard ratios for gynecological, endometrial, and ovarian cancers.

    “Another extensive meta-analysis ascertained a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies (gynecological cancer: HR = 0.60, 95% CI: 0.49–0.74; endometrial cancer: HR = 0.65, 95% CI: 0.50–0.85; ovarian cancer: HR = 0.47, 95% CI: 0.27–0.82).203”

    From Drug repurposing for cancer therapy (2024) · cites this paper as [203]

    The Discussion section on cancer risk (page not provided) reports no significant association between metformin use and the occurrence of gynecological, endometrial, or ovarian cancer in women with diabetes. The cited hazard ratios appear instead in the Discussion section on prognosis, where they describe overall survival among patients with cancer, not cancer occurrence. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 60

  1. [1]Kocarnik JM Compton K Dean FE Fu W Gaw BL Harvey JD. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol (2022) 8(3): 420–44. doi: 10.1001/jamaoncol.2021.6987 PMC8719276 34967848 · DOI
  2. [2]Cohen PA Jhingran A Oaknin A Denny L. Cervical Cancer. Lancet. (2019) 393(10167): 169–82. doi: 10.1016/S0140-6736(18)32470-X 30638582 · DOI
  3. [3]Buskwofie A David-West G Clare CA. A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc (2020) 112(2): 229–32. doi: 10.1016/j.jnma.2020.03.002 32278478 · DOI
  4. [4]He WQ Li C. Recent Global Burden of Cervical Cancer Incidence and Mortality, Predictors, and Temporal Trends. Gynecol Oncol (2021) 163(3): 583–92. doi: 10.1016/j.ygyno.2021.10.075 34688503 · DOI
  5. [5]Castle PE Einstein MH Sahasrabuddhe VV. Cervical Cancer Prevention and Control in Women Living With Human Immunodeficiency Virus. CA Cancer J Clin (2021) 71(6): 505–26. doi: 10.3322/caac.21696 PMC10054840 34499351 · DOI
  6. [6]Qiu H Cao S Xu R. Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison With the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Commun (Lond). (2021) 41(10): 1037–48. doi: 10.1002/cac2.12197 PMC8504144 34288593 · DOI
  7. [7]Moore K Brewer MA. Endometrial Cancer: Is This a New Disease? Am Soc Clin Oncol Educ Book (2017) 37: 435–42. doi: 10.1200/EDBK_175666 28561715 · DOI
  8. [8]Trojano G Olivieri C Tinelli R Damiani GR Pellegrino A Cicinelli E. Conservative Treatment in Early Stage Endometrial Cancer: A Review. Acta Biomed (2019) 90(4): 405–10. doi: 10.23750/abm.v90i4.7800 PMC7233769 31910163 · DOI
  9. [9]Penny SM. Ovarian Cancer: An Overview. Radiol Technol (2020) 91(6): 561–75. 32606233
  10. [10]Lheureux S Braunstein M Oza AM. Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine. CA Cancer J Clin (2019) 69(4): 280– 304. doi: 10.3322/caac.21559 31099893 · DOI
  11. [11]Lv Z Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). (2020) 11: 191. doi: 10.3389/fendo.2020.00191 32425881 PMC7212476 · DOI
  12. [12]Mossmann D Park S Hall MN. mTOR Signalling and Cellular Metabolism are Mutual Determinants in Cancer. Nat Rev Cancer. (2018) 18(12): 744–57. doi: 10.1038/s41568-018-0074-8 30425336 · DOI · Paper page
  13. [14]Ma R Yi B Riker AI Xi Y. Metformin and Cancer Immunity. Acta Pharmacol Sin (2020) 41(11): 1403–9. doi: 10.1038/s41401-020-00508-0 PMC7656961 32868904 · DOI
  14. [15]Rêgo DF Pavan LM Elias ST De Luca Canto G Guerra EN. Effects of Metformin on Head and Neck Cancer: A Systematic Review. Oral Oncol (2015) 51(5): 416–22. doi: 10.1016/j.oraloncology.2015.01.007 25636350 · DOI
  15. [16]De A Kuppusamy G. Metformin in Breast Cancer: Preclinical and Clinical Evidence. Curr problems cancer. (2020) 44(1): 100488. doi: 10.1016/j.currproblcancer.2019.06.003 31235186 · DOI
  16. [17]Broadhurst PJ Hart AR. Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use. Digestive Dis Sci (2018) 63(11): 2840–52. doi: 10.1007/s10620-018-5233-y 30159732 · DOI
  17. [19]Zhang ZJ Zheng ZJ Shi R Su Q Jiang Q Kip KE. Metformin for Liver Cancer Prevention in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab (2012) 97(7): 2347–53. doi: 10.1210/jc.2012-1267 22523334 · DOI
  18. [20]Lengyel E Litchfield LM Mitra AK Nieman KM Mukherjee A Zhang Y. Metformin Inhibits Ovarian Cancer Growth and Increases Sensitivity to Paclitaxel in Mouse Models. Am J obstetrics gynecol (2015) 212(4): 479.e1–.e10. doi: 10.1016/j.ajog.2014.10.026 PMC4387077 25446664 · DOI
  19. [21]Rattan R Graham RP Maguire JL Giri S Shridhar V. Metformin Suppresses Ovarian Cancer Growth and Metastasis With Enhancement of Cisplatin Cytotoxicity In Vivo. Neoplasia (New York NY) (2011) 13(5): 483–91. doi: 10.1593/neo.11148 PMC3084625 21532889 · DOI
  20. [22]Shuai Y Li C Zhou X. The Effect of Metformin on Gastric Cancer in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Clin Transl Oncol (2020) 22(9): 1580–90. doi: 10.1007/s12094-020-02304-y 32060719 · DOI
  21. [24]Tseng CH. Metformin Reduces Ovarian Cancer Risk in Taiwanese Women With Type 2 Diabetes Mellitus. Diabetes/metabolism Res Rev (2015) 31(6): 619–26. doi: 10.1002/dmrr.2649 25820555 · DOI
  22. [25]Bodmer M Becker C Meier C Jick SS Meier CR. Use of Metformin and the Risk of Ovarian Cancer: A Case-Control Analysis. Gynecol Oncol (2011) 123(2): 200–4. doi: 10.1016/j.ygyno.2011.06.038 21802715 · DOI
  23. [26]Becker C Jick SS Meier CR Bodmer M. Metformin and the Risk of Endometrial Cancer: A Case-Control Analysis. Gynecol Oncol (2013) 129(3): 565–9. doi: 10.1016/j.ygyno.2013.03.009 23523618 · DOI
  24. [27]Deng Y Wang J Li W Xiong W Wang X. Efficacy of Metformin in the Treatment of Estrogen-Dependent Endometrial Carcinoma Complicated With Type 2 Diabetes Mellitus and Analysis of its Prognosis. J BUON Off J Balkan Union Oncol (2020) 25(3): 1534–40. 32862601
  25. [28]Hanprasertpong J Jiamset I Geater A Peerawong T Hemman W Kornsilp S. The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus. Int J gynecol Cancer Off J Int Gynecol Cancer Society. (2017) 27(1): 131–7. doi: 10.1097/IGC.0000000000000855 27870711 · DOI
  26. [29]Seebacher V Bergmeister B Grimm C Koelbl H Reinthaller A Polterauer S. The Prognostic Role of Metformin in Patients With Endometrial Cancer: A Retrospective Study. Eur J obstetrics gynecol Reprod Biol (2016) 203: 291–6. doi: 10.1016/j.ejogrb.2016.06.013 27423029 · DOI
  27. [30]Garcia C Yao A Camacho F Balkrishnan R Cantrell LA. A SEER-Medicare Analysis of the Impact of Metformin on Overall Survival in Ovarian Cancer. Gynecol Oncol (2017) 146(2): 346–50. doi: 10.1016/j.ygyno.2017.05.006 28499649 · DOI
  28. [31]Takiuchi T Machida H Hom MS Mostofizadeh S Frimer M Brunette LL. Association of Metformin Use and Survival Outcome in Women With Cervical Cancer. Int J gynecol Cancer Off J Int Gynecol Cancer Society. (2017) 27(7): 1455–63. doi: 10.1097/IGC.0000000000001036 PMC7526033 29049093 · DOI
  29. [33]Shi J Liu B Wang H Zhang T Yang L. Association of Metformin Use With Ovarian Cancer Incidence and Prognosis: A Systematic Review and Meta-Analysis. Int J gynecol Cancer Off J Int Gynecol Cancer Society. (2019) 29(1): 140–6. doi: 10.1136/ijgc-2018-000060 30640696 · DOI · Paper page
  30. [34]Wen Q Zhao Z Wen J Zhou J Wu J Lei S. The Association Between Metformin Therapy and Risk of Gynecological Cancer in Patients: Two Meta-Analyses. Eur J obstetrics gynecol Reprod Biol (2019) 237: 33– 41. doi: 10.1016/j.ejogrb.2019.03.029 31009857 · DOI
  31. [35]Moher D Liberati A Tetzlaff J Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ (Clinical Res ed). (2009) 339: b2535. doi: 10.1136/bmj.b2535 PMC2714657 19622551 · DOI · Paper page
  32. [36]Ko EM Stürmer T Hong JL Castillo WC Bae-Jump V Funk MJ. Metformin and the Risk of Endometrial Cancer: A Population-Based Cohort Study. Gynecol Oncol (2015) 136(2): 341–7. doi: 10.1016/j.ygyno.2014.12.001 25499603 · DOI
  33. [37]Tseng CH. Metformin and Endometrial Cancer Risk in Chinese Women With Type 2 Diabetes Mellitus in Taiwan. Gynecol Oncol (2015) 138(1): 147–53. doi: 10.1016/j.ygyno.2015.03.059 25913129 · DOI
  34. [38]Franchi M Asciutto R Nicotra F Merlino L La Vecchia C Corrao G. Metformin, Other Antidiabetic Drugs, and Endometrial Cancer Risk: A Nested Case-Control Study Within Italian Healthcare Utilization Databases. Eur J Cancer Prev Off J Eur Cancer Prev Org (ECP). (2017) 26(3): 225–31. doi: 10.1097/CEJ.0000000000000235 27222938 · DOI
  35. [39]Gong Z Aragaki AK Chlebowski RT Manson JE Rohan TE Chen C. Diabetes, Metformin and Incidence of and Death From Invasive Cancer in Postmenopausal Women: Results From the Women's Health Initiative. Int J cancer. (2016) 138(8): 1915–27. doi: 10.1002/ijc.29944 PMC4830266 26616262 · DOI
  36. [40]Lemańska A Zaborowski M Spaczyński M Nowak-Markwitz E. Do Endometrial Cancer Patients Benefit From Metformin Intake? Ginekologia polska (2015) 86(6): 419–23. doi: 10.17772/gp/2397 26255448 · DOI
  37. [41]Arima R Marttila M Hautakoski A Arffman M Sund R Ilanne-Parikka P. Antidiabetic Medication, Statins and the Risk of Endometrioid Endometrial Cancer in Patients With Type 2 Diabetes. Gynecol Oncol (2017) 146(3): 636–41. doi: 10.1016/j.ygyno.2017.06.011 28645427 · DOI
  38. [42]Al Hilli MM Bakkum-Gamez JN Mariani A Cliby WA Mc Gree ME Weaver AL. The Effect of Diabetes and Metformin on Clinical Outcomes is Negligible in Risk-Adjusted Endometrial Cancer Cohorts. Gynecol Oncol (2016) 140(2): 270–6. doi: 10.1016/j.ygyno.2015.11.019 26607780 · DOI
  39. [43]Wang SB Lei KJ Liu JP Jia YM. Continuous Use of Metformin can Improve Survival in Type 2 Diabetic Patients With Ovarian Cancer: A Retrospective Study. Medicine. (2017) 96(29): e7605. doi: 10.1097/MD.0000000000007605 28723808 PMC5521948 · DOI
  40. [44]Han K Pintilie M Lipscombe LL Lega IC Milosevic MF Fyles AW. Association Between Metformin Use and Mortality After Cervical Cancer in Older Women With Diabetes. Cancer epidemiol Biomarkers Prev Publ Am Assoc Cancer Research cosponsored by Am Soc Prev Oncol (2016) 25(3): 507–12. doi: 10.1158/1055-9965.EPI-15-1008 26721670 · DOI
  41. [45]Tseng CH. Metformin Use and Cervical Cancer Risk in Female Patients With Type 2 Diabetes. Oncotarget. (2016) 7(37): 59548–55. doi: 10.18632/oncotarget.10934 PMC5312330 27486978 · DOI
  42. [46]Ezewuiro O Grushko TA Kocherginsky M Habis M Hurteau JA Mills KA. Association of Metformin Use With Outcomes in Advanced Endometrial Cancer Treated With Chemotherapy. PloS One (2016) 11(1): e0147145. doi: 10.1371/journal.pone.0147145 26788855 PMC4720394 · DOI
  43. [47]Urpilainen E Marttila M Hautakoski A Arffman M Sund R Ilanne-Parikka P. The Role of Metformin and Statins in the Incidence of Epithelial Ovarian Cancer in Type 2 Diabetes: A Cohort and Nested Case-Control Study. BJOG an Int J obstetrics gynaecol (2018) 125(8): 1001–8. doi: 10.1111/1471-0528.15151 29412502 · DOI
  44. [48]Luo J Beresford S Chen C Chlebowski R Garcia L Kuller L. Association Between Diabetes, Diabetes Treatment and Risk of Developing Endometrial Cancer. Br J cancer. (2014) 111(7): 1432–9. doi: 10.1038/bjc.2014.407 PMC4183842 25051408 · DOI
  45. [49]Hall C Stone RL Gehlot A Zorn KK Burnett AF. Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. Int J gynecol Cancer Off J Int Gynecol Cancer Society. (2016) 26(2): 313–7. doi: 10.1097/IGC.0000000000000603 26588235 · DOI
  46. [50]Insin P Prueksaritanond N. Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients With Diabetes. Asian Pacific J Cancer Prev APJCP. (2018) 19(5): 1295–302. doi: 10.22034/APJCP.2018.19.5.1295 PMC6031835 29802690 · DOI
  47. [51]Currie CJ Poole CD Jenkins-Jones S Gale EA Johnson JA Morgan CL. Mortality After Incident Cancer in People With and Without Type 2 Diabetes: Impact of Metformin on Survival. Diabetes Care (2012) 35(2): 299– 304. doi: 10.2337/dc11-1313 22266734 PMC3263862 · DOI
  48. [52]Urpilainen E Marttila M Hautakoski A Arffman M Sund R Ilanne-Parikka P. Prognosis of Ovarian Cancer in Women With Type 2 Diabetes Using Metformin and Other Forms of Antidiabetic Medication or Statins: A Retrospective Cohort Study. BMC cancer. (2018) 18(1): 767. doi: 10.1186/s12885-018-4676-z 30055585 PMC6064082 · DOI
  49. [53]Ko EM Walter P Jackson A Clark L Franasiak J Bolac C. Metformin is Associated With Improved Survival in Endometrial Cancer. Gynecol Oncol (2014) 132(2): 438–42. doi: 10.1016/j.ygyno.2013.11.021 24269517 · DOI
  50. [54]Nevadunsky NS Van Arsdale A Strickler HD Moadel A Kaur G Frimer M. Metformin Use and Endometrial Cancer Survival. Gynecol Oncol (2014) 132(1): 236–40. doi: 10.1016/j.ygyno.2013.10.026 PMC3904540 24189334 · DOI
  51. [55]Romero IL McCormick A McEwen KA Park S Karrison T Yamada SD. Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity. Obstetrics gynecol (2012) 119(1): 61–7. doi: 10.1097/AOG.0b013e3182393ab3 PMC3244683 22183212 · DOI
  52. [56]Kumar S Meuter A Thapa P Langstraat C Giri S Chien J. Metformin Intake is Associated With Better Survival in Ovarian Cancer: A Case-Control Study. Cancer. (2013) 119(3): 555–62. doi: 10.1002/cncr.27706 PMC3553259 23208739 · DOI
  53. [57]Bar D Lavie O Stein N Feferkorn I Shai A. The Effect of Metabolic Comorbidities and Commonly Used Drugs on the Prognosis of Patients With Ovarian Cancer. Eur J obstetrics gynecol Reprod Biol (2016) 207: 227–31. doi: 10.1016/j.ejogrb.2016.09.005 27890326 · DOI
  54. [58]Park JY Lim MC Baek MH Park YH Kim S. Impact of Metformin on Survival Outcome in Ovarian Cancer: A Nationwide Population-Based Cohort Study. J gynecol Oncol (2021) 32(4): 42–52. doi: 10.3802/jgo.2021.32.e65 PMC8192236 34085799 · DOI
  55. [59]Zhang K Bai P Dai H Deng Z. Metformin and Risk of Cancer Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Prim Care Diabetes. (2021) 15(1): 52–8. doi: 10.1016/j.pcd.2020.06.001 32605879 · DOI · Paper page
  56. [60]Zou G Bai J Li D Chen Y. Effect of Metformin on the Proliferation, Apoptosis, Invasion and Autophagy of Ovarian Cancer Cells. Exp Ther Med (2019) 18(3): 2086–94. doi: 10.3892/etm.2019.7803 PMC6704536 31452705 · DOI
  57. [61]Cui Y Zhou J Rong F. Combination of Metformin and RG7388 Enhances Inhibition of Growth and Induction of Apoptosis of Ovarian Cancer Cells Through the PI3K/AKT/mTOR Pathway. Biochem Biophys Res Commun (2020) 533(4): 665–71. doi: 10.1016/j.bbrc.2020.09.135 33051060 · DOI
  58. [62]Yang X Huang M Zhang Q Chen J Li J Han Q. Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling. Cell Transplant. (2021) 30: 9636897211027819. doi: 10.1177/09636897211027819 34238029 PMC8274104 · DOI
  59. [63]Xue J Li L Li N Li F Qin X Li T. Metformin Suppresses Cancer Cell Growth in Endometrial Carcinoma by Inhibiting PD-L1. Eur J Pharmacol (2019) 859: 172541. doi: 10.1016/j.ejphar.2019.172541 31319067 · DOI
  60. [64]Qiang P Shao Y Sun YP Zhang J Chen LJ. Metformin Inhibits Proliferation and Migration of Endometrial Cancer Cells Through Regulating PI3K/AKT/MDM2 Pathway. Eur Rev Med Pharmacol Sci (2019) 23(4): 1778–85. doi: 10.26355/eurrev_201902_17140. 30840303 · DOI

Cited by

Sorted by citations

Authors
Yao, K., Zheng, H., & Li, T.
Affiliations
Sichuan University (CN)
Corresponding author
Li, Tao
ORCID
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2022-07-11
Volume
12
Pages
942380-942380
ISSN
2234-943X (ISSN-L)
DOI
10.3389/fonc.2022.942380
PMC
PMC9309370
OpenAlex
W4285014024
Cited by
18
References
4
Citations by year
2026: 6 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 1
FWCI
0.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
metformin, gynecologic cancer, diabetes mellitus, cancer risk, overall survival, progression-free survival, recurrence-free survival, cancer-specific survival, ovarian cancer, endometrial cancer, adjuvant therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review